Abstract
Background: Medulloepithelioma (ME) is a rare embryonal tumor predominantly located in the eye or in the central nervous system without an established treatment.Case presentation: We report of a case of a localized peripheral ME treated with conventional and high dose chemotherapy, surgery and local radiotherapy. At relapse, the tumor tissue revealed a different molecular signature compared to the initial tumor mass. This molecular signature revealed a high expression of platelet derived growth factor receptor (PDGFR). Sorafenib plus irinotecan and temozolomide was started with a 5 month progression free survival.Conclusion: Our experience suggests a possible role of sorafenib or different PDGFR inhibitors in ME. Targeting treatment could represent an adjuvant and/or alternative therapy for ME and other rare tumors. © 2014 De Pasquale et al.; licensee BioMed Central Ltd.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 1-6 |
| Numero di pagine | 6 |
| Rivista | Journal of Translational Medicine |
| Volume | 12 |
| Numero di pubblicazione | 1 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2014 |
All Science Journal Classification (ASJC) codes
- Biochimica, Genetica, Biologia Molecolare Generali
Keywords
- PDGF
- Peripheral medulloepithelioma
- Target therapy
- Treatment